Supported by an unrestricted scientific grant from Centocor. Fabian Schnitzler received a research grant by ECCO (European Crohn's and Colitis Organisation).
Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease†
Article first published online: 1 APR 2009
Copyright © 2009 Crohn's & Colitis Foundation of America, Inc.
Inflammatory Bowel Diseases
Volume 15, Issue 9, pages 1295–1301, September 2009
How to Cite
Schnitzler, F., Fidder, H., Ferrante, M., Noman, M., Arijs, I., Van Assche, G., Hoffman, I., Van Steen, K., Vermeire, S. and Rutgeerts, P. (2009), Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis, 15: 1295–1301. doi: 10.1002/ibd.20927
- Issue published online: 19 AUG 2009
- Article first published online: 1 APR 2009
- Manuscript Accepted: 16 FEB 2009
- Manuscript Received: 12 FEB 2009
- 3Review article: altering the natural history of Crohn's disease — evidence for and against current therapies. Aliment Pharm Ther. 2006; 25: 3–12., , .
- 17SONIC: a randomised, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gut. 2008; 57( Suppl II): A1.–, , , et al.
- 18Long-term outcome of treatment with infliximab in 614 Crohn's disease patients: results from a single centre cohort. Gut. 2008 (in press)., , , et al.